Sandvig-Pharma ApS: Financial statements 2021
CVR: 40667687
Source: annual report 2021, Danish Business Authority
01/05/2020 – 30/04/2021
Sandvig-Pharma ApS (CVR 40667687) has filed annual accounts for 2021. In 2021, the company reported a net result of DKK 0. Equity in the 2021 report amounted to DKK 50,000. The solvency ratio was 100%.
- Profit/Loss
- DKK 0
- Equity
- DKK 50,000
- Total Assets
- DKK 50,000
Official annual report
Find more companies like Sandvig-Pharma ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
Sandvig-Pharma ApS has published its interim report for the period May 1, 2021 – June 30, 2021.
On July 6, 2021, the company changed its name from Zibo Pharma ApS to Z-Pharma ApS.
As of January 16, 2021, Jeannette Buchard Denker is registered as adm. dir. of Sandvig-Pharma ApS.
As of January 16, 2021, Gunhild Nyborg Pedersen has stepped down as adm. dir. of Sandvig-Pharma ApS.
On January 16, 2021, the company changed its name from Universe of Dreams ApS to Zibo Pharma ApS.
Sandvig-Pharma ApS has published its interim report for the period July 12, 2019 – April 30, 2020.
About Sandvig-Pharma ApS
Sandvig-Pharma ApS is a Danish company of the type Anpartsselskab based in Aabenraa, founded in 2019. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Z-Pharma ApS and Zibo Pharma ApS. The management consists of Lars Buchard Denker. The company is owned by Sandvig Capital ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -4,539,181 and a net result of DKK -3,988,029 compared with DKK -5,566,003 the year before. Equity in the 2025 report amounted to DKK -17,841,900.